drugset / Trial / NCT00250432

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

NCT00250432

Phase 3 Completed 204 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)

Timeline

Start
2006-01
Primary completion
2008-01
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Caspofungin Other / unclassified 50 mg Intravenous
Subject Caspofungin Other / unclassified 150 mg Intravenous

Indications